Pharmaceutical - Respiratory and Pulmonary, Research

Filter

Popular Filters

1 to 25 of 86 results

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

Stallergenes publishes review of grass pollen tablet confirming efficacy

Stallergenes publishes review of grass pollen tablet confirming efficacy

24-06-2014

French allergen specialist Stallergenes has released comprehensive new data on the 5-grass pollen immunotherapy…

FrancePharmaceuticalResearchRespiratory and PulmonaryStallergenes

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

23-06-2014

UK-based biotechnology company Verona Pharma says that the Phase IIa clinical trial to evaluate the efficacy…

PharmaceuticalResearchRespiratory and PulmonaryUKVerona Pharma

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

16-06-2014

Denmark-based allergy specialist ALK Abello partner for Japan, Torii Pharmaceutical, has completed its…

ALK AbelloJapanPharmaceuticalRegulationResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

11-06-2014

UK pharma giant GlaxoSmithKline and US partner Theravance have released positive results from two Phase…

Breo ElliptaGlaxoSmithKlineIncruse ElliptaPharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryTheravance

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

10-06-2014

Danish allergy specialist ALK-Abello has presented positive key trial results on its new sublingual allergy…

Alk-AbelloPharmaceuticalResearchRespiratory and PulmonarySLIT-tablet

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

20-05-2014

UK pharma major GlaxoSmithKline has released data showing the safety and efficacy of the addition of…

AdvairGlaxoSmithKlineHealth Medical PharmaHealth Medical PharmaIncruse ElliptaMedicinePharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapyUK

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

30-04-2014

Swiss drug major Novartis today announced positive first results from the Phase III head-to-head LANTERN…

COPDEuropeHealth Medical PharmaMedicineNovartisPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretideUltibro Breezhaler

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

28-04-2014

Swiss drug major Novartis has announced encouraging top-line results from its Phase IV INSTEAD switch…

EuropeHealth Medical PharmaMedicineModerate COPDNovartisOnbrezPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretide

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

14-03-2014

GlaxoSmithKline and Theravance today announced positive results from three Phase III studies with their…

Advair DiskusAnoro ElliptaGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretide

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

13-03-2014

UK pharma giant GlaxoSmithKline says that a pivotal Phase III study of mepolizumab, an investigational…

GlaxoSmithKlinemepolizumabPharmaceuticalResearchRespiratory and Pulmonary

Report: Global cystic fibrosis market value to treble by 2019

12-03-2014

The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

KaloBios tanks as it halts KB003 development for asthma

31-01-2014

USA-based KaloBios Pharmaceuticals revealed disappointing top line results from a Phase II study on KB003…

KaloBios PharmaceuticalsKB003PharmaceuticalResearchRespiratory and Pulmonary

Sanofi and MAbImprove LabEx collaborate on rare lung disease

Sanofi and MAbImprove LabEx collaborate on rare lung disease

24-01-2014

French drug major Sanofi and MAbImprove Laboratoire d'Excellence (LabEx), coordinated by France’s Universite…

PharmaceuticalRare diseasesResearchRespiratory and PulmonarySanofi

Study shows Fostair has comparable efficacy to Seretide in asthma patients

Study shows Fostair has comparable efficacy to Seretide in asthma patients

20-01-2014

A study has shown that asthma patients may be switched from Seretide to Fostair at an equivalent or lower…

Chiesi FarmaceuticiFostairGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretideUK

Bayer CEO calls for greater appreciation of innovation

Bayer CEO calls for greater appreciation of innovation

19-11-2013

Advances in cancer therapy are expected in the next years, thanks in particular to treatment using antibody-drug…

BayerNephrology and HepatologyOncologyPharmaceuticalResearchRespiratory and Pulmonary

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

30-10-2013

AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

Stallergenes and DBV Technologies collaborate in birch pollen allergy research

18-10-2013

French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

1 to 25 of 86 results

Back to top